Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
Sanofi Winthrop Industrie
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
June 23, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
June 23, 2026
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
June 22, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
June 19, 2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
June 12, 2026
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
June 10, 2026
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
June 8, 2026
Press Release: Sanofi launches 2026 global employee stock purchase plan
June 4, 2026
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
May 28, 2026
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
May 18, 2026
1
2
3
Next Page
→